MedTrace Logo

DAVID II (Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial II)

NCT00187187 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2019-02-04

No results posted yet for this study

Summary

The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure as compared to patients with ventricular backup pacing.

Conditions

Interventions

DEVICE

Implantable Defibrillator (ICD)

Implantable Defibrillator (ICD)

DEVICE

Implantable Defibrillator (ICD)

Implantable Defibrillator (ICD)

Sponsors & Collaborators

Principal Investigators

  • Allfred P Hallstrom, PhD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2007-09-30
Completion
2007-09-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00187187 on ClinicalTrials.gov